The following clinical trials have been or are being conducted by ReceptaBio:
01. RebmAb100 for Ovarian Tumor in Platinum-Resistant/Refractory Patients – Phase II
The protocol of the clinical study RCP-Ov-01.06, "A Phase II Study of Hu3s193 Therapy for Patients with Platinum-Refractory or –Resistant, Ovary, Primary Peritoneum and Uterine Tubes Adenocarcinoma" was prepared by Dr. Óren Smaletz, MD, then ReceptaBio Medical Director, in collaboration with scientists from the company Biocancer, led by Prof. Dr. Alberto Wainstein, PhD. Conducting the study was approved by the research ethics committees (RECs) of the participating centers and by ANVISA. The study was also registered in the United States to meet the requirements of the US Food and Drug Administration (FDA) within the IND (Investigational New Drug) process; it is registered on clinicaltrials.gov under the number NCT00617773 (Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer).
This clinical study gave rise to a poster, presented in 2011 at the ASCO (American Society of Clinical Oncology) conference, the most important event in the area of oncology, and was later published in Gynecologic Oncology, in 2016 (A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma).